Tweet
Jan 5, 2010 - 20:01
Europe seeks to offload flu vaccines
Western European countries, including Switzerland, are queuing up to shift surplus stocks of the H1N1 flu vaccine after low public demand.
Amid controversy over its costly swine flu vaccine campaign, France said on Monday it wanted to cancel 50 million of the 94 million doses it had ordered because of over-supply. These latest moves could hit drugmakers? profits, say analysts.
France had originally planned to spend ?869 million (SFr1.3 billion) on 94 million vaccine doses, estimating that each individual would need two shots. But only five million French people out of a population of 65 million have been vaccinated and European health authorities have said one vaccine dose is sufficient.
The French move follows decisions by Switzerland, Spain, Germany and the Netherlands last month to review orders for vaccines to which they committed.
Switzerland, which has a population of 7.7 million, ordered 13 million doses of vaccine from GlaxoSmithKline (GSK) and Novartis, worth SFr84 million ($81 million).
In December the government said it planned to donate to the World Health Organization (WHO) or sell to other countries some 4.5 million excess doses of the swine flu vaccine due to the low uptake.
Only a small share of the initial order has been used. Most of the remainder is stocked by the federal and cantonal authorities, which say 15-30 per cent of the population have been vaccinated.
?Negotiations are ongoing with a view to selling or donating our stocks,? Jean-Louis Zurcher, Federal Health Office spokesman, told swissinfo.ch.
Zurcher refused to say which countries were interested and could not confirm whether Switzerland, like France, was in negotiations with pharmaceutical firms to cancel or return surplus vaccines.
?A lot of money was invested in the vaccines but the pandemic situation could have been much worse,? he added.
Shifting stocks
Elsewhere, Germany is also trying to offload surplus stocks and renegotiate orders placed during an early phase of the pandemic. It is due to start talks with GSK in Berlin on Thursday to try to negotiate a 50 per cent cut in the 50 million doses of the Pandemrix vaccine to be delivered.
The Netherlands announced in November that it would sell 19 million of the 34 million doses that it had ordered.
Spain is also seeking to return unused vaccines. It says its contracts with Novartis (22 million doses), GSK (14.7 million) and Sanofi-Aventis (400,000) include clauses that allow it to return surplus vaccines if they prove to be unnecessary.
A British health ministry spokesman told Agence France Presse on Sunday that sales of the vaccine were also being considered.
Pessimistic analysts
In light of the recent moves, analysts are increasingly gloomy about vaccine manufacturers' revenue and earnings prospects from the H1N1 pandemic.
Morgan Stanley analysts said the latest French cuts underlined declining demand for H1N1 vaccines and translated into a ?modest near-term risk to earnings? at GSK, Sanofi and Novartis.
?Longer term, the evident overcapacity with H1N1 should limit any multiple expansion related to income associated with pandemic flu," they added.
Sales of H1N1 vaccines have been a windfall for pharmaceutical companies. GSK is expected to be the single biggest beneficiary with anticipated sales of SFr3.7 billion by the end of the first quarter of 2010, according to analysts. Sanofi and Novartis have been forecast to earn an estimated SFr1.1 billion and SFr628 million, respectively.
The latest cancellations in Europe could reduce those numbers. But a spokesman for Sanofi said his company expected to replace the lost sales in France with orders from different parts of the world.
Glaxo declined to comment on the commercial impact of the latest developments but a spokeswoman said the British group was in discussions with governments about orders.
?Novartis will evaluate government requests on a case-by-case basis within the framework of the contractual agreements which we consider binding,? said Eric Althoff, head of media relations at the Swiss pharmaceutical giant.
?Extravagant fiasco?
The French government move came after intense criticism from politicians and scientists. The French opposition Socialist Party described the national campaign as an ?extravagant fiasco? and demanded a parliamentary investigation.
Elsewhere, Council of Europe member states are considering whether to launch an inquiry into pharmaceutical companies? influence on the global swine flu campaign.
The WHO's "false pandemic" flu campaign was "one of the greatest medicine scandals of the century," said German doctor Wolfgang Wodarg, chairman of the Council of Europe Parliamentary Assembly (Pace) Health Committee, who tabled the motion to be debated on January 25.
Simon Bradley, swissinfo.ch and agencies
Europe seeks to offload flu vaccines
Western European countries, including Switzerland, are queuing up to shift surplus stocks of the H1N1 flu vaccine after low public demand.
Amid controversy over its costly swine flu vaccine campaign, France said on Monday it wanted to cancel 50 million of the 94 million doses it had ordered because of over-supply. These latest moves could hit drugmakers? profits, say analysts.
France had originally planned to spend ?869 million (SFr1.3 billion) on 94 million vaccine doses, estimating that each individual would need two shots. But only five million French people out of a population of 65 million have been vaccinated and European health authorities have said one vaccine dose is sufficient.
The French move follows decisions by Switzerland, Spain, Germany and the Netherlands last month to review orders for vaccines to which they committed.
Switzerland, which has a population of 7.7 million, ordered 13 million doses of vaccine from GlaxoSmithKline (GSK) and Novartis, worth SFr84 million ($81 million).
In December the government said it planned to donate to the World Health Organization (WHO) or sell to other countries some 4.5 million excess doses of the swine flu vaccine due to the low uptake.
Only a small share of the initial order has been used. Most of the remainder is stocked by the federal and cantonal authorities, which say 15-30 per cent of the population have been vaccinated.
?Negotiations are ongoing with a view to selling or donating our stocks,? Jean-Louis Zurcher, Federal Health Office spokesman, told swissinfo.ch.
Zurcher refused to say which countries were interested and could not confirm whether Switzerland, like France, was in negotiations with pharmaceutical firms to cancel or return surplus vaccines.
?A lot of money was invested in the vaccines but the pandemic situation could have been much worse,? he added.
Shifting stocks
Elsewhere, Germany is also trying to offload surplus stocks and renegotiate orders placed during an early phase of the pandemic. It is due to start talks with GSK in Berlin on Thursday to try to negotiate a 50 per cent cut in the 50 million doses of the Pandemrix vaccine to be delivered.
The Netherlands announced in November that it would sell 19 million of the 34 million doses that it had ordered.
Spain is also seeking to return unused vaccines. It says its contracts with Novartis (22 million doses), GSK (14.7 million) and Sanofi-Aventis (400,000) include clauses that allow it to return surplus vaccines if they prove to be unnecessary.
A British health ministry spokesman told Agence France Presse on Sunday that sales of the vaccine were also being considered.
Pessimistic analysts
In light of the recent moves, analysts are increasingly gloomy about vaccine manufacturers' revenue and earnings prospects from the H1N1 pandemic.
Morgan Stanley analysts said the latest French cuts underlined declining demand for H1N1 vaccines and translated into a ?modest near-term risk to earnings? at GSK, Sanofi and Novartis.
?Longer term, the evident overcapacity with H1N1 should limit any multiple expansion related to income associated with pandemic flu," they added.
Sales of H1N1 vaccines have been a windfall for pharmaceutical companies. GSK is expected to be the single biggest beneficiary with anticipated sales of SFr3.7 billion by the end of the first quarter of 2010, according to analysts. Sanofi and Novartis have been forecast to earn an estimated SFr1.1 billion and SFr628 million, respectively.
The latest cancellations in Europe could reduce those numbers. But a spokesman for Sanofi said his company expected to replace the lost sales in France with orders from different parts of the world.
Glaxo declined to comment on the commercial impact of the latest developments but a spokeswoman said the British group was in discussions with governments about orders.
?Novartis will evaluate government requests on a case-by-case basis within the framework of the contractual agreements which we consider binding,? said Eric Althoff, head of media relations at the Swiss pharmaceutical giant.
?Extravagant fiasco?
The French government move came after intense criticism from politicians and scientists. The French opposition Socialist Party described the national campaign as an ?extravagant fiasco? and demanded a parliamentary investigation.
Elsewhere, Council of Europe member states are considering whether to launch an inquiry into pharmaceutical companies? influence on the global swine flu campaign.
The WHO's "false pandemic" flu campaign was "one of the greatest medicine scandals of the century," said German doctor Wolfgang Wodarg, chairman of the Council of Europe Parliamentary Assembly (Pace) Health Committee, who tabled the motion to be debated on January 25.
Simon Bradley, swissinfo.ch and agencies
